Xaira Therapeutics
AI-powered biotech platform using protein design to discover novel therapeutic molecules.
About
Xaira Therapeutics, founded by Marc Tessier-Lavigne (ex-Stanford president) with ARCH Ventures/Foresite Labs, uses AI protein design to discover drugs for hard-to-treat targets. David Baker (2024 Nobel laureate) co-founder. Launched with $1B committed funding (April 2024).
Technology stack
detected 2026-06-08Est. monthly stack spend~$140/mo
CDN
Cloudflare
Email
Google Workspace
Stack
Webflow
Cookie consent
OneTrust
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Xaira Therapeutics do?
Xaira Therapeutics, founded by Marc Tessier-Lavigne (ex-Stanford president) with ARCH Ventures/Foresite Labs, uses AI protein design to discover drugs for hard-to-treat targets. David Baker (2024 Nobel laureate) co-founder. Launched with $1B committed funding (April 2024).
How much funding has Xaira Therapeutics raised?
Xaira Therapeutics has raised a total of $1.0B in funding. The most recent round on record is Seed.
Where is Xaira Therapeutics headquartered?
Xaira Therapeutics is headquartered in San Francisco, United States.
When was Xaira Therapeutics founded?
Xaira Therapeutics was founded in 2024.
What industry does Xaira Therapeutics operate in?
Xaira Therapeutics operates in Artificial Intelligence, Biotechnology, Drug Discovery, Protein Design, Therapeutics, NeoLab.